BOLTON SECURITIES CORPORATION’s Pacific Biosciences PACB Stock Holding History

BOLTON SECURITIES CORPORATION’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$142	Buy	+120	New	+$184	﹤0.01%	1844

Other funds holding PACB

ARK Investment Management St. Petersburg, Florida $15.5B AUM 50.54% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return

Edmond de Rothschild Holding Chambesy, Switzerland $8.18B AUM 23.81% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

BOLTON SECURITIES CORPORATION's PACB Position: Q1 2025 in Review

BOLTON SECURITIES CORPORATION opened a new position in Pacific Biosciences (PACB) in Q1 2025: 120 shares worth $142. The stake represents ﹤0.01% of the portfolio and ranks #1844 among its holdings.

226 funds tracked by Wall St. Rank hold PACB as of Q1 2025.

BOLTON SECURITIES CORPORATION held 120 shares of Pacific Biosciences worth $142 as of Q1 2025.
Pacific Biosciences was a new BOLTON SECURITIES CORPORATION position in Q1 2025.
Pacific Biosciences made up ﹤0.01% of BOLTON SECURITIES CORPORATION's portfolio in Q1 2025, its #1844 holding.
226 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2025.

Based on BOLTON SECURITIES CORPORATION's 13F filing for Q1 2025, filed 12 Nov 2026.